Johnson & Johnson (US)

Alle Meldungen

10.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson MedTech Launches VOLT™ Plating System

Next-Generation Plating System combines flexibility and stability for advanced fracture care 1-4* across orthopaedic procedures 5,6 WEST CHESTER, Penn. – October 10, 2024 – Johnson & Johnson MedTech, a global leader in orthopaedic technologies...

Zur Pressemeldung auf www.jnj.com
09.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson Completes Acquisition of V-Wave

Adds V-Wave’s Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease NEW BRUNSWICK, N.J.— October 9, 2024 — Johnson &...

Zur Pressemeldung auf www.jnj.com
07.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson Statement on the SunRISe-2 Study

The SunRISe-2 study in patients with muscle-invasive bladder cancer (MIBC) who are not receiving radical cystectomy was a bold approach to disrupt the established standard of care in chemoradiation in this difficult-to-treat population. Following...

Zur Pressemeldung auf www.jnj.com
07.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research

Lynne Maquat, Ph.D., and Alexander Varshavsky, Ph.D., to receive 2024 Dr. Paul Janssen Award for their fundamental discoveries about regulated degradation of RNA and proteins. New Brunswick, N.J. (Sept. 25, 2024) – Johnson & Johnson today...

Zur Pressemeldung auf www.jnj.com
04.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue

No safety issues identified to date Raritan, N.J. (October 4, 2024) – Johnson & Johnson announced today it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the...

Zur Pressemeldung auf www.jnj.com
04.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

New Brunswick, N.J., October 4 th , 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12 th , at the InterContinental Boston in Boston, MA. Biljana Naumovic, President,...

Zur Pressemeldung auf www.jnj.com
03.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session

· Oral session, featuring nipocalimab results in adolescents living with gMG represents first FcRn blocker data to be presented focusing on this population with high unmet medical need · Oral and poster sessions to include multiple new analyses...

Zur Pressemeldung auf www.jnj.com
02.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO ® -based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Results from CEPHEUS study highlight DARZALEX FASPRO ® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the first FDA-approved treatment regimen for newly...

Zur Pressemeldung auf www.jnj.com
02.10

Johnson & Johnson (US) Johnson & Johnson (US)

ERLEADA ® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, PORTUGAL, October 2, 2024 – Johnson & Johnson (NYSE: JNJ) today announced the results of...

Zur Pressemeldung auf www.jnj.com
02.10

Johnson & Johnson (US) Johnson & Johnson (US)

Johnson & Johnson Announces Collaborative Effort with USAID to Strengthen the Health Workforce Across Latin America and the Caribbean

Memorandum of Understanding will support the Americas Health Corps in its goal to train 500,000 health workers to help build strong and resilient health systems and bring more communities closer to care Washington, D.C. (October 2, 2024) – Johnson...

Zur Pressemeldung auf www.jnj.com

Wem folgen?

MG Motor
Folgen
Universität Wien
Folgen
WWF Österreich
Folgen

Mehr anzeigen

Trends

Black Friday
Folgen
Aktionstag
Folgen
Tesla
Folgen
Advent
Folgen
Menschenrechte
Folgen
Unwetter
Folgen
Home Office
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info